News coverage about Ra Pharmaceuticals (NASDAQ:RARX) has been trending somewhat positive this week, Accern reports. The research firm rates the sentiment of press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Ra Pharmaceuticals earned a media sentiment score of 0.03 on Accern’s scale. Accern also assigned news articles about the company an impact score of 47.3383010592328 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Several equities analysts recently commented on the company. SunTrust Banks reissued a “buy” rating on shares of Ra Pharmaceuticals in a research report on Thursday, March 15th. BMO Capital Markets reduced their price target on Ra Pharmaceuticals from $34.00 to $31.00 and set an “outperform” rating on the stock in a research report on Thursday, March 15th. Credit Suisse Group reduced their price target on Ra Pharmaceuticals from $16.00 to $14.00 and set an “outperform” rating on the stock in a research report on Tuesday, February 13th. ValuEngine downgraded Ra Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. Finally, Zacks Investment Research downgraded Ra Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, January 11th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $19.50.
RARX stock traded up $0.16 during midday trading on Wednesday, hitting $6.29. 139,636 shares of the company’s stock were exchanged, compared to its average volume of 254,865. Ra Pharmaceuticals has a 12-month low of $4.78 and a 12-month high of $27.84. The company has a market capitalization of $188.88, a PE ratio of -2.58 and a beta of 2.31.
In other news, major shareholder Ra Capital Healthcare Fund Lp purchased 2,500,000 shares of the stock in a transaction dated Wednesday, February 14th. The stock was acquired at an average cost of $6.00 per share, for a total transaction of $15,000,000.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, major shareholder Enterprise Associates 13 L. New purchased 2,000,000 shares of the stock in a transaction dated Friday, February 16th. The stock was purchased at an average price of $6.00 per share, with a total value of $12,000,000.00. The disclosure for this purchase can be found here. 14.50% of the stock is owned by insiders.
TRADEMARK VIOLATION WARNING: This piece of content was originally posted by Week Herald and is owned by of Week Herald. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at https://weekherald.com/2018/04/18/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-ra-pharmaceuticals-rarx-stock-price.html.
About Ra Pharmaceuticals
Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.
Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.